2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2865

Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission
Abstract Number: 894

Cancer Risk in Ankylosing Spondylitis in United States Medicare Beneficiaries: Detection of a Chronic Non Steroidal Anti-Inflammatory Drug Use Signature
Abstract Number: 2741

Candidate Biomarkers in ANCA-Associated Vasculitis Identified Using a Proteomic Approach
Abstract Number: 566

Capillary Blood Based Methotrexate Polyglutamate Assay for Monitoring Low Dose Methotrexate Therapy in Rheumatic Diseases
Abstract Number: 33

Card9 Is a Critical Regulator of Autoimmune Arthritis in SKG Mice
Abstract Number: 801

Cardiac Autonomic Modulation at Rest and during Orthostatic Stress in Systemic Sclerosis Patients
Abstract Number: 1589

Cardiac Biomarkers and Carotid Atherosclerosis and Its Progression in Psoriatic Disease
Abstract Number: 2989

Cardiac Involvement in Systemic Vasculitis: A Retrospective Pathological Study
Abstract Number: 518

Cardiometabolic Risk Factors Impact on the Cardioprotective Effect of Apelin on Systolic and Diastolic Function, in Patients with Rheumatoid Arthritis
Abstract Number: 1880

Cardiovascular (CV) Risk Factors and Atherosclerotic CV Events Among Incident Cases of Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)
Abstract Number: 764

Cardiovascular Disease in SLE at One Center between 1981 and 2016. a Population-Based Study Highlighting the Importance of Disease Duration and Age at Diagnosis
Abstract Number: 509

Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative
Abstract Number: 2817

Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis
Abstract Number: 2253

Cardiovascular Disease, Other Purported Risk Factors, and Allopurinol-Associated Severe Cutaneous Adverse Reactions: A General Population-Based Cohort Study
Abstract Number: 2242

Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].